Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07203287
PHASE4

Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease

Sponsor: The University of Texas Medical Branch, Galveston

View on ClinicalTrials.gov

Summary

The purpose of the study is to determine which combination of neuromuscular blocking agent and reversal agent is safer to use during anesthesia for patients with chronic kidney disease. The main question it aims to answer is "The use of Cisatracurium with neostigmine leads to less post-operative pulmonary complications than Rocuronium with sugammadex."

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

490

Start Date

2025-08-26

Completion Date

2027-08-26

Last Updated

2026-02-23

Healthy Volunteers

Yes

Interventions

DRUG

Rocuronium

Will be assessing neuromuscular blockade with rocuronium and reversal with sugammadex

DRUG

Cisatracurium

Will be assessing neuromuscular blockade with neostigmine and reversal with neostigmine

DRUG

Sugammadex

Will be assessing neuromuscular blockade with rocuronium and reversal with sugammadex

DRUG

Neostigmine

Will be assessing neuromuscular blockade with neostigmine and reversal with neostigmine

Locations (1)

University of Texas Medical Branch

Galveston, Texas, United States